During REM sleep, the body enters a state of paralysis. This can pose a danger for patients with weakened diaphragms due to neuromuscular diseases.

CRISPR-edited iPSCs uncover early mitochondrial defects shared across ALS mutations, revealing pathways that could guide future treatments.

Patients with less neuronal damage, determined by low spinal fluid pNFH, had a 48% reduction in the risk of death by adding IL-2 to riluzole.

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

The ALS Network, formerly ALS Golden West, in partnership with the ALS CURE Project, Livermore Lab Foundation, RDM Positive Impact Foundation, and Stanford University, is supporting a $300,000 ...